CA3110652A1 - Methods of using a phenoxypropylamine compound to treat pain - Google Patents
Methods of using a phenoxypropylamine compound to treat pain Download PDFInfo
- Publication number
- CA3110652A1 CA3110652A1 CA3110652A CA3110652A CA3110652A1 CA 3110652 A1 CA3110652 A1 CA 3110652A1 CA 3110652 A CA3110652 A CA 3110652A CA 3110652 A CA3110652 A CA 3110652A CA 3110652 A1 CA3110652 A1 CA 3110652A1
- Authority
- CA
- Canada
- Prior art keywords
- pain
- compound
- subject
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726800P | 2018-09-04 | 2018-09-04 | |
| US62/726,800 | 2018-09-04 | ||
| PCT/US2019/049492 WO2020101790A2 (en) | 2018-09-04 | 2019-09-04 | Methods of using a phenoxypropylamine compound to treat pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3110652A1 true CA3110652A1 (en) | 2020-05-22 |
Family
ID=69641874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3110652A Pending CA3110652A1 (en) | 2018-09-04 | 2019-09-04 | Methods of using a phenoxypropylamine compound to treat pain |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11766430B2 (https=) |
| EP (1) | EP3846812A2 (https=) |
| JP (2) | JP7439096B2 (https=) |
| KR (1) | KR102886521B1 (https=) |
| CN (1) | CN112955145A (https=) |
| AU (2) | AU2019381269B2 (https=) |
| BR (1) | BR112021004030A2 (https=) |
| CA (1) | CA3110652A1 (https=) |
| CL (1) | CL2021000531A1 (https=) |
| GB (1) | GB2591937B (https=) |
| IL (1) | IL281166B2 (https=) |
| MA (1) | MA53565A (https=) |
| MX (1) | MX2021002590A (https=) |
| UA (1) | UA129837C2 (https=) |
| WO (1) | WO2020101790A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021026480A2 (pt) | 2019-06-28 | 2022-02-08 | Univ Texas | Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer |
| JP2024520463A (ja) | 2021-05-24 | 2024-05-24 | メディコン ファーマシューティカルズ，インコーポレイテッド | 化学療法誘発性末梢神経障害に関連する疼痛の処置 |
| EP4272826A3 (en) * | 2021-05-24 | 2024-01-17 | Medicon Pharmaceuticals, Inc. | Treating pain associated with diabetic peripheral neuropathy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4207343A (en) | 1978-06-22 | 1980-06-10 | Eli Lilly And Company | 1-Phenyl-3-(substituted phenoxy)propylamines |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ES2244438T3 (es) * | 1999-05-24 | 2005-12-16 | Mitsubishi Pharma Corporation | Compuestos de fenoxipropilamina. |
| ES2220582T3 (es) | 1999-12-20 | 2004-12-16 | Eli Lilly And Company | Derivados de piperidina y su uso como antagonistas de receptor de serotonina. |
| ATE409475T1 (de) * | 2001-02-20 | 2008-10-15 | Dinan Timothy Gerard | Behandlung von fibromyalgie mit pindolol |
| DK1423168T3 (da) * | 2001-09-03 | 2006-05-15 | Newron Pharm Spa | Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse |
| US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| SA08280759B1 (ar) | 2007-01-10 | 2011-05-04 | سولفاي فارماسوتيكالز بي . في | مركبات من عوامل مضادة لشبيه القنب – cb1 ومكونات هيكلية من مثبطات إعادة إمتصاص السيروتونين بأندلابين أو فلوكسامين |
| TW201039815A (en) | 2009-04-13 | 2010-11-16 | Resolvyx Pharmaceuticals Inc | Compositions and methods for the treatment of inflammation |
| RU2424799C1 (ru) | 2010-03-29 | 2011-07-27 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" | Способ коррекции депрессивных расстройств производными тиетан-1,1-диоксида в эксперименте |
| DK2948143T3 (da) | 2013-01-24 | 2021-07-26 | Minerva Neurosciences Inc | Anvendelse af phenoxypropylaminforbindelser til behandling af depression |
| WO2017205399A1 (en) * | 2016-05-25 | 2017-11-30 | Minerva Neurosciences, Inc. | (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders |
-
2019
- 2019-09-04 CN CN201980072400.4A patent/CN112955145A/zh active Pending
- 2019-09-04 WO PCT/US2019/049492 patent/WO2020101790A2/en not_active Ceased
- 2019-09-04 CA CA3110652A patent/CA3110652A1/en active Pending
- 2019-09-04 MA MA053565A patent/MA53565A/fr unknown
- 2019-09-04 UA UAA202101703A patent/UA129837C2/uk unknown
- 2019-09-04 KR KR1020217009800A patent/KR102886521B1/ko active Active
- 2019-09-04 AU AU2019381269A patent/AU2019381269B2/en active Active
- 2019-09-04 EP EP19858688.5A patent/EP3846812A2/en active Pending
- 2019-09-04 GB GB2104738.6A patent/GB2591937B/en active Active
- 2019-09-04 US US16/559,687 patent/US11766430B2/en active Active
- 2019-09-04 MX MX2021002590A patent/MX2021002590A/es unknown
- 2019-09-04 JP JP2021536676A patent/JP7439096B2/ja active Active
- 2019-09-04 BR BR112021004030-7A patent/BR112021004030A2/pt unknown
- 2019-09-04 IL IL281166A patent/IL281166B2/en unknown
-
2021
- 2021-03-03 CL CL2021000531A patent/CL2021000531A1/es unknown
-
2023
- 2023-07-13 US US18/351,682 patent/US20240016790A1/en not_active Abandoned
-
2024
- 2024-02-14 JP JP2024020391A patent/JP2024056875A/ja active Pending
-
2025
- 2025-05-30 AU AU2025204043A patent/AU2025204043A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11766430B2 (en) | 2023-09-26 |
| IL281166A (en) | 2021-04-29 |
| KR102886521B1 (ko) | 2025-11-17 |
| WO2020101790A3 (en) | 2020-07-09 |
| UA129837C2 (uk) | 2025-08-20 |
| US20200069672A1 (en) | 2020-03-05 |
| IL281166B1 (en) | 2025-04-01 |
| AU2025204043A1 (en) | 2025-06-19 |
| JP2024056875A (ja) | 2024-04-23 |
| WO2020101790A2 (en) | 2020-05-22 |
| GB2591937B (en) | 2023-06-07 |
| EP3846812A2 (en) | 2021-07-14 |
| US20240016790A1 (en) | 2024-01-18 |
| JP7439096B2 (ja) | 2024-02-27 |
| MX2021002590A (es) | 2021-05-31 |
| GB202104738D0 (en) | 2021-05-19 |
| AU2019381269B2 (en) | 2025-03-06 |
| IL281166B2 (en) | 2025-08-01 |
| KR20210061357A (ko) | 2021-05-27 |
| BR112021004030A2 (pt) | 2021-06-22 |
| AU2019381269A1 (en) | 2021-03-18 |
| MA53565A (fr) | 2021-07-14 |
| CN112955145A (zh) | 2021-06-11 |
| GB2591937A (en) | 2021-08-11 |
| CL2021000531A1 (es) | 2021-10-08 |
| JP2021536506A (ja) | 2021-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240016790A1 (en) | Methods of using a phenoxypropylamine compound to treat pain | |
| RS60152B1 (sr) | Tapentadol za sprečavanje i lečenje depresije i anksioznosti | |
| JP2023523569A (ja) | 神経学的および精神障害の治療方法 | |
| CA2999965A1 (en) | Apilimod compositions and methods for using same | |
| CN108463224A (zh) | sGC刺激剂用于胃肠功能障碍治疗的应用 | |
| KR20260020944A (ko) | 수면 개선 조성물 및 이용 방법 | |
| CN105209445B (zh) | 治疗运动障碍和相关病症的方法 | |
| RU2007119067A (ru) | Средство для лечения синдрома раздраженного кишечника с преобладанием диареи | |
| KR20070029740A (ko) | 통증 치료를 위한 레복세틴의 용도 | |
| US20110244057A1 (en) | Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions | |
| JP2018515547A (ja) | オピオイドとｎ−アシルエタノールアミンの組み合わせ | |
| RU2797615C2 (ru) | Способы применения феноксипропиламинового соединения для лечения боли | |
| TWI874362B (zh) | 使用苯氧丙胺化合物治療疼痛的方法 | |
| CN110191706A (zh) | 治疗利多卡因无效病症和低钾血病症的治疗方法 | |
| US12139402B2 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| JP2022526755A (ja) | 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法 | |
| RU2799049C2 (ru) | Способы лечения изменений поведения | |
| HK40093852A (zh) | 阿片类物质和n-酰基乙醇胺的组合 | |
| WO2017064098A1 (en) | Products for treating psychogenic pain disorders | |
| JP2008545616A (ja) | ジスキネジーの阻害または治療 | |
| HK1113092A (en) | Use of reboxetine for the treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240812 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20240812 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240830 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240830 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240830 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241109 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241125 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241223 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250411 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250829 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250829 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250922 |